European pharma's first quarter financials have been delivered in a challenging and volatile operating environment, where the war in Ukraine and the impact of COVID-19 continue to have an impact, where inflation is up, as are energy and raw material costs and where political tensions are high.
Nevertheless, the continent's drugmakers delivered healthy growth in Q1. In the UK, AstraZeneca PLC continued to profit from the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?